Not Yet RecruitingPhase 2ACTRN12607000192482

EPI-12323 for the treatment of symptomatic moderate to severe asthma

A Randomized, Double-Blind, Parallel Study of the effects on asthma control of a Once Daily Dosing of EPI-12323 versus Placebo in Symptomatic Moderate to Severe Asthmatics on Low-Dose Inhaled Corticosteroids

Sponsor

Epigenesis Pharmaceuticals, LLC, USA

Enrollment

214 participants

Start Date

Jun 1, 2007

Study Type

Interventional

Conditions

Symptomatic moderate to severe asthma

Summary

This study examines the safety and the ability of a new asthma medicine, EPI-12323, to improve asthma control, pulmonary function and symptoms in patients with symptomatic moderate to severe asthma.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests EPI-12323, an investigational treatment for moderate to severe symptoms of an enlarged prostate (benign prostatic hyperplasia). This study is open to both men and women aged 18 to 65. Participation involves taking the study medication and attending visits for symptom assessments and safety monitoring.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Inhalation of EPI-12323 (35 mg/mL) + 400 ucg budesonide once daily for six weeks

Locations(1)

United States of America

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000192482